Literature DB >> 31560910

Pharmacoresistance - Epidemiology, mechanisms, and impact on epilepsy treatment.

Mubeen Janmohamed1, Martin J Brodie2, Patrick Kwan3.   

Abstract

Understanding the natural history of and factors associated with pharmacoresistant epilepsy provides the foundation for formulating mechanistic hypotheses that can be evaluated to drive the development of novel treatments. This article reviews the modern definition of drug-resistant epilepsy, its prevalence and incidence, risk factors, hypothesized mechanisms, and the implication of recognizing pharmacoresistance in therapeutic strategies. This article is part of the special issue entitled 'New Epilepsy Therapies for the 21st Century - From Antiseizure Drugs to Prevention, Modification and Cure of Epilepsy'.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Epidemiology; Epilepsy; Mechanisms; Pharmacoresistance; Risk factors; Treatment

Mesh：

Substances：

Year:  2019        PMID： 31560910     DOI： 10.1016/j.neuropharm.2019.107790

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN： 0028-3908            Impact factor:   5.250


  24 in total

1.  Inhibition of TRPC3 channels by a novel pyrazole compound confers antiseizure effects.

Authors:  Marwa M Nagib; Sicheng Zhang; Nelufar Yasmen; Lexiao Li; Ruida Hou; Ying Yu; Vijay K Boda; Zhongzhi Wu; Wei Li; Jianxiong Jiang
Journal:  Epilepsia       Date:  2022-02-18       Impact factor: 5.864

2.  OV329, a novel highly potent γ-aminobutyric acid aminotransferase inactivator, induces pronounced anticonvulsant effects in the pentylenetetrazole seizure threshold test and in amygdala-kindled rats.

Authors:  Malte Feja; Sebastian Meller; Lillian S Deking; Edith Kaczmarek; Matthew J During; Richard B Silverman; Manuela Gernert
Journal:  Epilepsia       Date:  2021-10-07       Impact factor: 5.864

Review 3.  TRPC channels as emerging targets for seizure disorders.

Authors:  Ying Yu; Wei Li; Jianxiong Jiang
Journal:  Trends Pharmacol Sci       Date:  2022-07-12       Impact factor: 17.638

Review 4.  Molecular Mechanisms in the Genesis of Seizures and Epilepsy Associated With Viral Infection.

Authors:  Wolfgang Löscher; Charles L Howe
Journal:  Front Mol Neurosci       Date:  2022-05-09       Impact factor: 6.261

5.  Current Principles in the Management of Drug-Resistant Epilepsy.

Authors:  Nathan A Shlobin; Josemir W Sander
Journal:  CNS Drugs       Date:  2022-05-20       Impact factor: 6.497

Review 6.  Adenosine and Ketogenic Treatments.

Authors:  David N Ruskin; Masahito Kawamura; Susan A Masino
Journal:  J Caffeine Adenosine Res       Date:  2020-09-16

Review 7.  Development of cannabidiol as a treatment for severe childhood epilepsies.

Authors:  Claire M Williams; Gary J Stephens
Journal:  Br J Pharmacol       Date:  2020-10-27       Impact factor: 8.739

8.  Sub-additive (antagonistic) interaction of lacosamide with lamotrigine and valproate in the maximal electroshock-induced seizure model in mice: an isobolographic analysis.

Authors:  Jarogniew J Łuszczki; Maria Kondrat-Wróbel; Mirosław Zagaja; Sławomir Karwan; Hubert Bojar; Zbigniew Plewa; Magdalena Florek-Łuszczki
Journal:  Pharmacol Rep       Date:  2020-06-07       Impact factor: 3.024

9.  Interactions among Lacosamide and Second-Generation Antiepileptic Drugs in the Tonic-Clonic Seizure Model in Mice.

Authors:  Katarzyna Załuska-Ogryzek; Paweł Marzęda; Paula Wróblewska-Łuczka; Magdalena Florek-Łuszczki; Zbigniew Plewa; Hubert Bojar; Dorota Zolkowska; Jarogniew J Łuszczki
Journal:  Int J Mol Sci       Date:  2021-05-24       Impact factor: 5.923

10.  Independent Community Pharmacists' Experience in Offering Pharmacogenetic Testing.

Authors:  Susanne B Haga; Rachel Mills; Jivan Moaddeb; Yiling Liu; Deepak Voora
Journal:  Pharmgenomics Pers Med       Date:  2021-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.